| DC73721 |
BMS-737 |
BMS-737 (BMS737) is a potent, , selective, non-steroidal, reversible inhibitor of CYP17 lyase, 11-fold selectivity for CYP17 lyase over CYP17 hydroxylase. |
|
| DC73722 |
DLCI-1 |
DLCI-1 is a potent and selective CYP2A6 inhibitor with IC50 of 17 nM, 15-765-fold selectivity other major hepatic CYP enzymes. |
|
| DC73723 |
DLCI-1 dihydrochloride |
DLCI-1 dihydrochloride is a potent and selective CYP2A6 inhibitor with IC50 of 17 nM, 15-765-fold selectivity other major hepatic CYP enzymes. |
|
| DC73724 |
ODM-208 |
ODM-208 (ODM208) is a potent, selective, orally bioavailable CYP11A1 inhibitor, inhibits the biosynthesis of pregnenolone with IC50 of 15 nM in NCI-H295R cells. |
|
| DC73725 |
ODM-209 |
ODM-209 (ODM209) is a potent, selective, orally bioavailable inhibitor of CYP11A1 (cholesterol side-chain cleavage enzyme) with potential antineoplastic activity, inhibits the biosynthesis of pregnenolone. |
|
| DC73726 |
TPP-IOA |
TPP-IOA is a specific inhibitor of cytochrome c (cyt c) peroxidase activity, inhibits peroxidase activity of cardiolipin-induced cytochrome c peroxidase activity with IC50 of 5 uM. |
|
| DC73727 |
AZD7687 |
AZD7687 (AZD-7687) is a potent, selective DGAT1 inhibitor with IC50 of 80 nM (hDGAT1), >400-fold selectivity over hACAT1. |
|
| DC73728 |
TP-020 |
TP-020 is a potent, selective, orally active inhibitor of monoacylglycerol acyltransferase (MGAT2) with IC50 of 7.8 and 2.4 nM for human and mouse MGAT2, respectively. |
|
| DC73729 |
AX8819 |
AX8819 is a potent, specific DPP-2 inhibitor with IC50 of 0.88 nM, highly selective for DPP II over all of the other DPP enzymes. |
|
| DC73730 |
ICeD-1 |
ICeD-1 is a potent DPP9 inhibitor capable of killing HIV-1 infected peripheral blood mononuclear cells, activates the caspase recruitment domain family member 8 (CARD8) inflammasome. |
|
| DC73731 |
TEI-8362 |
TEI-8362 is a potent, selective inhibitor of human neutrophil elastase (HNE) with Ki value of 1.38 nM and IC50 of 1.9 nM. |
|
| DC73732 |
ARN15381 |
ARN15381 is a potent, multitarget FAAH inhibitor/D3 partial agonist with low nanomolar range activity, decreases nicotine self-administration in male rats. |
|
| DC73733 |
UCM1341 |
UCM1341 (UCM 1341) is a bivalent ligand with melatonin receptor agonist (hMT1/hMT2, pKi=9.11/8.77) and fatty acid amide hydrolase (FAAH) inhibitory activity (rFAAH IC5=0.85 nM). |
|
| DC73734 |
Fasnall benzenesulfonate |
Fasnall benzenesulfonate is a potent, selective fatty acid synthase (FASN) inhibitor with IC50 of 3.71 uM for purified human FASN isolated from the BT474 cell line. |
|
| DC73735 |
FASstatin |
FASstatin (FASNi-8) is an orally bioavailable small-molecule inhibitor of fatty acid synthase (FASN), directly binds FASN with SPR KD of 16 uM, potentiates TRIM56-mediated FASN ubiquitination. |
|
| DC73736 |
NJNU-0069 |
NJNU-0069 is a specific small-molecule inducer of major histocompatibility complex class II (MHC-II), directly binds to the MAT domain of FASN (Kd=32.1 uM). |
|
| DC73737 |
NJNU-0069-003 |
NJNU-0069-003 is a specific small-molecule inducer of major histocompatibility complex class II (MHC-II), directly binds to the MAT domain of FASN with Kd of 7.98 uM. |
|
| DC73738 |
GKA23 |
GKA23 is a potent, small molecule glucokinase (GK) activator with EC50 of 152 nM for glucokinase activation in 5 mM glucose, increases glucose uptake in primary rat hepatocytes with EC50 of 201 nM. |
|
| DC73739 |
GKM-001 |
GKM-001 is a potent, liver-selective small molecule activator of glucokinase (GKA), demonstrates glucose lowering effect without hypoglycemia in normal and type II diabetes mellitus (T2DM). |
|
| DC73740 |
TMG-123 |
TMG-123 (TMG123) is a potent small molecule activator of glucokinase (GK) with EC50 of 0.35 and 0.32 uM for human liver and pancreas GK, respectively. |
|
| DC73741 |
MZ-101
Featured
|
MZ-101 is a potent, selective inhibitor of glycogen synthase 1 (GYS1) with IC50 of 41 nM (human GYS1), with no inhibition against GYS2. |
|
| DC73743 |
SRK2128 |
SRK2128 (SRK 2128) is a highly potent HMG-CoA reductase degrader with EC50 of 84 nM, potently induce degradation of HMG-CoA reductase. |
|
| DC73744 |
ADAM9i
Featured
|
ADAM9i is a specific small molecule inhibitor of ADAM9 protein with binding KD of 5.9 uM and enzyme IC50 of 5.2 uM, promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy. |
|
| DC73745 |
AZD1236 |
AZD1236 is a potent, selective MMP-9 and MMP-12 inhibitor with IC50 of 4.5 and 6.1 nM respectively, >10-fold selectivity to MMP-2 and MMP-13 and >350-fold selectivity to other MMPs. |
|
| DC73746 |
BAY-9835
Featured
|
BAY-9835 is the first orally bioavailable ADAMTS7 inhibitor with IC50 of 6 nM, which is selective against a range of off-targets and metalloproteases except for ADAMTS12. |
|
| DC73747 |
CID 3117694 |
CID 3117694 is a selective, non-competitive inhibitor of ADAM10 with IC50 of 1.1 uM, does not inhibit ADAM17. |
|
| DC73748 |
IPR-179 |
IPR-179 (ACT-03) is a potent, BBB-permeable, selective gelatinase (MMP2 and MMP9) inhibitor with IC50 of 656 nM and 310 nM, respectively. |
|
| DC73749 |
JTP-96193 |
JTP-96193 (JTP96193) is a potent, selective TNF-α converting enzyme (TACE/ADAM17) inhibitor with IC50 of 5.4 nM, >1800-fold selectivity against ADAM10. |
|
| DC73750 |
MMP118 |
MMP118 is a potent, selective and orally bioavailable matrix metalloproteinase-12 (MMP-12) inhibitor with IC50 of 1.0 nM (hMMP-12), 1980- and 154-fold selectivity over MMP-13 and MMP-8 respectively. |
|
| DC73751 |
MMP408 |
MMP408 (MMP 408) is a potent, selective matrix metalloprotease 12 (MMP-12) inhibitor with IC50 of 2.0 nM (human MMP-12), 60-fold selectivity over MMP-13. |
|
